Search
Keyhole limpet hemocyanin
go.drugbank.com/drugs/DB05299ApprovedInvestigationalWithdrawnKeyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. … Keyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet.
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Temafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnIt was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three … Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class.
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnIt was rejected for approval for use in the United States. … Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884ApprovedIt is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305] … [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Hydroflumethiazide
go.drugbank.com/drugs/DB00774ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10602ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot Fluvirin 2015-2016Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB10999ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 KitGivosiran
go.drugbank.com/drugs/DB15066Approved[L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder … in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity.
Dexfenfluramine
go.drugbank.com/drugs/DB01191ApprovedIllicitWithdrawnFor a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.
Synonyms: d-N-ethyl-α-methyl-m-trifluoromethylphenethylamine, (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine